VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will present at the following investor conferences in June: Jefferies Virtual Healthcare Conference Date: Wednesday, June 2 nd at 2:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will present at the following investor conferences in June:
| Jefferies Virtual Healthcare Conference | |
| Date: | Wednesday, June 2nd at 2:30 p.m. ET |
| Webcast: | https://wsw.com/webcast/jeff174/vtgn/1876041 |
| Registration: | To attend the virtual conference, please contact your Jefferies representative. |
| William Blair 41st Annual Virtual Growth Stock Conference | |
| Date: | Thursday, June 3rd at 3:00 p.m. ET |
| Webcast: | https://wsw.com/webcast/blair58/vtgn/1959945 |
| Registration: | To attend the virtual conference, please contact your William Blair representative. |
For more information regarding these investor conferences, please visit the sponsor’s conference website.
About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.
Company Contacts
Mark A. McPartland / Mark Flather
VistaGen Therapeutics, Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com
